TR201809128T4 - Gram-pozitif bakterilere spesifik bağlanan bileşikler. - Google Patents
Gram-pozitif bakterilere spesifik bağlanan bileşikler. Download PDFInfo
- Publication number
- TR201809128T4 TR201809128T4 TR2018/09128T TR201809128T TR201809128T4 TR 201809128 T4 TR201809128 T4 TR 201809128T4 TR 2018/09128 T TR2018/09128 T TR 2018/09128T TR 201809128 T TR201809128 T TR 201809128T TR 201809128 T4 TR201809128 T4 TR 201809128T4
- Authority
- TR
- Turkey
- Prior art keywords
- sequence
- seq
- antibody
- light chain
- heavy chain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 241000192125 Firmicutes Species 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 claims 18
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 241000191940 Staphylococcus Species 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000004475 Arginine Chemical group 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003680 valines Chemical group 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Bu buluş, Gram-pozitif bakterilere spesifik olarak bağlanabilen gelişmiş bağlanma bileşikleri ortaya koymaktadır. Tamamen insan menşeli olup bu sayede insanlara yönelik terapötik uygulamalarda kullanılabilecek olan bağlanma bileşikleri sunulmaktadır.
Claims (2)
1. Bir Staphylococcus türüne baglanma kabiliyetine sahip olan ve asagida belirtilenleri içeren bir izole antikor veya onun bir 5 fonksiyonel parçasi: (a) bir agir zincir CDRl sekansi olan RFAMS (SEKANS KOD NO.: 1), ve (b) bir agir zincir CDR2 sekansi olan 10 SINNGNNPYYARSVQY (SEKANS KOD NO.: 2), ve (c) bir agir zincir CDR3 sekansi olan DHPSSGWPTFDS (SEKANS KOD NO.: 3), ve ((1) bir hafif zincir CDRl sekansi olan RASENVGDWLA (SEKANS KOD NO.: 4), ve 15 (e) bir hafif zincir CDR2 sekansi olan KTSILES (SEKANS KOD NO.: 5), ve (I) bir hafif zincir CDR3 sekansi olan X'in I veya M oldugu QHYXRFPYT (SEKANS KOD NO.: 6). 20
2. Istem l'e uygun antikor veya onun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi asagida belirtilenleri (i) asagida belirtilenleri içeren bir agir zincir degisken 25 domain sekansi: (a) EVQLLESGGGLVQPGGSLRLSCAASGFTL S (SEKANS KOD NO.: 38) sekansina sahip olan çerçeve l (FW1); (b) WVRQAPGRGLEWVA (SEKANS KOD NO.: 40) sekansina sahip olan çerçeve 2 (FW2); (c) RFTVSRDVSQNTVSLQMNNLRAEDSATYF CAK (SEKANS KOD NO.: 42) sekansina sahip olan çerçeve 3 (FW3); ve (d) WGPGTLVTVSS (SEKANS KOD NO.: 44) sekansina sahip olan çerçeve 4 (FW4); (ii) asagida belirtilenleri içeren bir hafif zincir degisken domain sekansi: (a) DIQLTQSPSALPASVGDRVSITC (SEKANS KOD NO.: 48) sekansina sahip olan çerçeve 1 (b) WYRQKPGKAPNLLIY (SEKANS KOD NO.: 50) sekansina sahip olan çerçeve 2 (FW2); (C) GVPSRFSGSGSGTEFTLTISSLQPDDFATYY C (SEKANS KOD NO.: 52) sekansina sahip olan çerçeve 3 (FW3); ve (d) FGQGTKLEIKRTV (SEKANS KOD NO.: 54) sekansina sahip olan çerçeve 4 (FW4); veya (a) DIQLTQSPSALPASVGDRVSITC (SEKANS KOD NO.: 48) sekansina sahip olan çerçeve l (b) WYRQKPGKAPNLLIY (SEKANS KOD NO.: 50) sekansina sahip olan çerçeve 2 (FW2); (c) GVPSRFSGSGSGTEFTLTISSLQPDDFATYY C (SEKANS KOD NO.: 52) sekansina sahip olan çerçeve 3 (FW3); ve (d) FGQGTKVEIKRTV (SEKANS KOD NO.: 59) sekansina sahip olan çerçeve 4 (FW4). Istem l'e uygun antikor veya oiiun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi asagida belirtilenleri içerir: (i) EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFA MSWVRQAPGRGLEWVASINNGNNPYYARSVQYR FTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPS SGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansi ile en az %70 oraninda sekans özdesligine sahip olan bir sekans içeren bir agir zincir degisken domain sekansi; (ii) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDWLAW YRQKPGKAPNLLIYKTSILESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKR TV (SEKANS KOD NO.: 8) sekansi ile en az %70 oraninda sekans özdesligine sahip olan bir sekans içeren bir hafif zincir degisken domain sekansi. Istem 3 ”e uygun antikor veya onun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVR QAPGRGLEWVASINNGNNPYYARSVQYRFTVSRDVSQN TVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansina sahip olan bir agir zincir degisken domaini içerir burada antikor vay onun fonksiyonel parçasi X'in 1 veya M DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQK PGKAPNLLIYKTSILESGVPSRFSGSGSGTEFTLTISSLQPD DFATYYCQHYXRFPYTFGQGTKVEIKRTV (SEKANS KOD NO.: 1 l) sekansina sahip olan bir hafif zincir degisken domaini içerir. Istem l'e uygun bir izole antikor veya onun fonksiyonel parçasi burada söz konusu antikor veya onun fonksiyonel parçasi istege bagli olarak insan kaynaklidir, ve burada Staphylococcus türü istege bagli olarak bir metisiline dirençli S. aureus (MRSA) veya bir inetisiline duyarli S. aureus (MSSA) veya bir vankomisine orta düzeyde duyarli S. aureus (VISA)°dir ve burada antikor veya bunun fonksiyonel parçasi asagida belirtilenlerden birini içerir: (a) EVQLLESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNN PYYARSVQYRFTVSRDVSQNTVSLQMNN LRAEDSATYFCAKDHPSSGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGVPSRFSG SGSGTEFTLTISSLQPDDFATYYCQHYXRFPY TFGQGTKVEIKRTV (SEKANS KOD NO.: 1 1) sekansini içeren bir hafif zincir degisken domaini; (a) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRTV (SEKANS KOD NO 8) sekansini içeren bir hafif zincir degisken domaini; veya (a) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir Zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRA (SEKANS KOD NO.: 10) sekansini içeren bir hafif zincir degisken domaini; veya (21) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKVEIKRTV (SEKANS KOD NO.: 11) sekansini içeren bir hafif zincir degisken domaini; veya (21) EVQLLESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRTV (SEKANS KOD NO 8) sekansini içeren bir hafif zincir degisken domaini; veya (a) EVQLLESGGGLVQPGGSLRLSCAASGF TL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRA (SEKANS KOD NO.: 10) sekansiiii içeren bir hafif zincir degisken domaini.
6. Asagida belirtilenleri içeren, istem l'e uygun bir izole antikor veya onun bir fonksiyonel parçasi: (a) SEKANS KOD NO.: 55 sekansini içeren bir agir zincir (Sekil 9A, rFl agir zinciri); ve (b) SEKANS KOD NO.: 57 sekansini içeren bir hafif zincir (Sekil 9B, rFl hafif zinciri).
7. Bir Staphylococcus türüne baglanma kabiliyetine sahip olan ve asagida belirtilenleri içeren ve asagidaki (i), (ii) ve (iii) sayili maddelerden herhangi birinde belirtilen ainino asit ikame(1er)ini bünyesinde barindiran bir izole antikor veya onun bir fonksiyonel parçasi: (a) bir agir zincir CDRl sekansi olan RFAMS (SEKANS KOD NO.: 1), ve (b) bir agir zincir CDR2 sekansi olan SINNGNNPYYARSVQY (SEKANS KOD NO.: 2), ve (0) bir agir zincir CDR3 sekansi olan DHPSSGWPTFDS (SEKANS KOD NO.: 3), ve (d) bir hafif zincir CDR] sekansi olan RASENVGDWLA (SEKANS KOD NO.: 4), ve (e) bir hafif zincir CDR2 sekansi olan KTSILES (SEKANS KOD NO.: 5), ve (f) bir hafif zincir CDR3 sekansi olan X'in 1 veya M oldugu QHYXRFPYT (SEKANS KOD NO.: 6); (i) "Kabat (1991)" eserinde gösterilen amino asit nuinaralandirma sistemine göre agir zincir degisken domaininde 53 numarali pozisyonda yer alan asparajinin baska bir amino asit ile ikamesi, amino asidin serin ile ikamesi; veya (ii) "Kabat (1991)" eserinde gösterilen amino asit nuinaralandirma sistemine göre agir zincir degisken domaininde 53 numarali pozisyonda yer alan asparajinin serin ile ikamesi, 114 numarali pozisyonda yer alan alaninin sistein ile ikamesi ve 222 numarali pozisyonda yer alan ar jininin lizin ile ikamesi; veya (iii) "Kabat (1991)" eserinde gösterilen amino asit numaralandirma sistemine göre hafif zincir degisken domaininde 205 numarali pozisyonda yer alan valinin sistein ile ikamesi, hafif zincir degisken domaininde 110 numarali pozisyonda yer alan alaniniii valin ile ikamesi ve hafif zincir degisken domaininde 104 numarali pozisyonda yer alan lösinin valin ile ikamesi. Asagida belirtileiileri içeren, istem 7'ye uygun bir izole antikor veya onun bir fonksiyonel parçasi: (a) SEKANS KOD NO.: 56 sekansini içeren bir agir zincir (Sekil 9A, rFl A1 14C); ve (b) SEKANS KOD NO.: 58 sekansini içeren bir hafif zincir (Sekil 9B, rFl V205G). Istem 1'e uygun antikorun bir fonksiyonel parçasini içeren bir bilesim olup, burada antikorun fonksiyonel parçasi bir tek domainli antikor, bir tek zincirli antikor, bir nanobody, bir unibody, bir tek zincirli degisken bölge fragmani (scFV), bir Fab fragmani ve bir F(ab')2 fragmani arasindan seçilir. Asagida belirtilenlerden birini kodlayaii bir izole, sentetik veya rekombinan iiükleik asit sekansi: (i) istem 1 ilâ 8'e uygun antikorlar veya bunun fonksiyonel parçalarindan herhangi biri; veya (ii) agir zincir CDRl, CDR2 veya CDR3 ya da hafif zincir CDRl, CDR2 veya CDR3 burada sekans asagida olusan grup arasindan seçilir: agir zincir CDRl sekansi cgctttgccatgagc (SEKANS KOD NO.: 12), agir zincir CDR2 sekansi (SEKANS KOD NO.: 13), agir zincir CDR3 sekansi gatcaccctagtagtggctggcccacctttgactcc (SEKANS KOD NO.: 14), hafif zincir CDRl sekansi cgggccagtgaaaacgttggtgactggttgg cc (SEKANS KOD NO.: 15), hafif zincir CDR2 sekansi aagacatctattctagaaagt (SEKANS KOD NO.: 16) ve hafif zincir CDR3 sekansi Caacactatatacgtttcccgtacact (SEKANS KOD NO.: 17). Istem lO'a uygun nükleik asidi içeren bir izole hücre. Bir ilaç ve/Veya profilaktik ajan olarak kullanim için, istemler 1 ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem lO'a uygun bir nükleik asit sekansi. Asagida belirtilen kullanim alanlarindan birinde kullanim için, isteniler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem lO'a uygun bir nükleik asit sekansi: (i) bir Gram-pozitif bakteri ile iliskili rahatsizligi tedavi etmeye ve/veya Önlemeye yönelik bir ilaç ve/veya profilaktik ajan olarak; veya (ii) bir Staphylococcus enfeksiyonunun in vivo ortamda teshisinde. Istemler 1 ilâ 8'de11 herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istein lO'a uygun bir nükleik asit sekansinin bir Gram-pozitif bakteri ile iliskili hastaligi tedavi etmeye ve/veya önlemeye yönelik bir ilaç ve/veya profilaktik a janin hazirlanma asamasinda kullanimi. Istemler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasinin ya da istem 10'a uygun bir nükleik asit sekansinin bulundugu ve ayrica bir faimasötik açidan kabul edilebilir tasiyici, seyreltici veya yardimci madde ihtiva eden bir farmasötik bilesim. Isteinler 1 ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi üretme kabiliyetine sahip olan bir izole veya rekombinan antikor üreten hücre. Istemler 1 ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi üretmek için olan ve istem 10'a uygun bir nükleik asit sekansi bulunan bir hücrenin temin edilmesi ve o hücrenin söz konusu nükleik asit sekansini translate etmesine izin vermek suretiyle bahsi geçen antikor veya fonksiyonel antikor parçasini üretmeye dayanan ve istege bagli olarak ayrica söz konusu antikor veya fonksiyonel antikor parçasinin hasat edildigi, saflastirildigi ve/Veya izole edildigi bir yöntem. Isteniler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem 10'a uygun bir nükleik asit sekansinin asagida belirtilen kullanim alanlarindan birinde in vitro ortamda kullanimi: (a) bir Staphylococcus enfeksiyonunun teshisi; veya (b) S. aureus ve/veya S. epiderinidis'in tespiti. Bir çözeltide bulunan S. aureus ve/Veya S. epiderinidis bakterilerini o çözeltiden isteinler l ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi kullanarak izole etmek için olan bir yöntem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22587809P | 2009-07-15 | 2009-07-15 | |
| EP09165558 | 2009-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201809128T4 true TR201809128T4 (tr) | 2018-07-23 |
Family
ID=41467048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/09128T TR201809128T4 (tr) | 2009-07-15 | 2010-07-15 | Gram-pozitif bakterilere spesifik bağlanan bileşikler. |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US20110020323A1 (tr) |
| EP (1) | EP2454284B1 (tr) |
| JP (3) | JP6192294B2 (tr) |
| KR (1) | KR101832201B1 (tr) |
| CN (2) | CN102666583B (tr) |
| AR (1) | AR077756A1 (tr) |
| AU (2) | AU2010271582B2 (tr) |
| BR (1) | BR112012000953A8 (tr) |
| CA (1) | CA2768204A1 (tr) |
| DK (1) | DK2454284T3 (tr) |
| EA (1) | EA031447B1 (tr) |
| ES (1) | ES2673323T3 (tr) |
| HK (1) | HK1222418A1 (tr) |
| HU (1) | HUE038277T2 (tr) |
| IL (3) | IL217497A (tr) |
| MX (1) | MX350234B (tr) |
| NZ (2) | NZ616921A (tr) |
| PL (1) | PL2454284T3 (tr) |
| SG (2) | SG177653A1 (tr) |
| SI (1) | SI2454284T1 (tr) |
| TR (1) | TR201809128T4 (tr) |
| TW (2) | TW201610153A (tr) |
| WO (1) | WO2011008092A2 (tr) |
| ZA (2) | ZA201200363B (tr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| ES2444465T5 (es) | 2005-12-09 | 2023-11-30 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos |
| TWI529247B (zh) | 2009-05-13 | 2016-04-11 | 建新公司 | 抗人類ｃｄ５２免疫球蛋白 |
| WO2011008093A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| HUE038277T2 (hu) | 2009-07-15 | 2018-10-29 | Aimm Therapeutics Bv | Gram-pozitív baktériumokra specifikus kötõvegyületek |
| ES2626671T3 (es) | 2010-12-02 | 2017-07-25 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| CN102559733A (zh) * | 2012-03-13 | 2012-07-11 | 黑龙江省科学院微生物研究所 | 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| AU2013341361A1 (en) | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| JP6371758B2 (ja) * | 2013-03-12 | 2018-08-08 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| SI3004162T1 (sl) * | 2013-05-31 | 2020-07-31 | Genentech, Inc. | Protitelesa in konjugati, ki so usmerjeni proti celični steni bakterij, v kateri je teihoična kislina |
| WO2014193722A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| HUE062317T2 (hu) | 2013-09-20 | 2023-10-28 | Bristol Myers Squibb Co | Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez |
| EP3572425A1 (en) | 2013-12-17 | 2019-11-27 | AIMM Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
| AU2015211480B2 (en) | 2014-01-31 | 2020-05-14 | Kling Biotherapeutics B.V. | Means and methods for producing stable antibodies |
| RU2017118792A (ru) * | 2014-12-03 | 2019-01-09 | Дженентек, Инк. | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение |
| RU2731055C2 (ru) * | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение |
| WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| KR20200010501A (ko) | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| US11280788B2 (en) | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
| KR102301987B1 (ko) * | 2019-11-14 | 2021-09-13 | 연세대학교 산학협력단 | 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트 |
| WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2192175A1 (en) | 1994-06-07 | 1995-12-21 | Ambrose Cheung | Surface protein of staphylococcus aureus |
| US6008341A (en) * | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| JP3638955B2 (ja) * | 1995-01-30 | 2005-04-13 | トルオク，ペーター | 連鎖球菌属からのリポテイコ酸を含有する抗腫瘍及び抗コレステロール製剤 |
| SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6680195B1 (en) * | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| KR100644953B1 (ko) | 1998-08-31 | 2006-11-10 | 인히비텍스, 인코포레이티드 | 다성분 백신 |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| CA2341177A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| KR100871330B1 (ko) | 1998-08-31 | 2008-12-01 | 더 프로보스트 펠로우스 앤드 스콜라스 오브 더 칼리지 오브 더 홀리 앤드 언디바이디드 트리니티 오브 퀸 엘리자베스 니어 더블린 | 응고효소 음성 포도상구균 유래의 폴리펩타이드 및폴리뉴클레오타이드 |
| US20030165527A1 (en) | 1998-12-22 | 2003-09-04 | Bengt Guss | Novel fibronectin-binding protein |
| US20040038327A1 (en) | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
| ATE524195T1 (de) * | 2001-01-26 | 2011-09-15 | Inhibitex Inc | Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen |
| GB0127983D0 (en) * | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
| CA2492671C (en) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| AU2003274972A1 (en) | 2002-09-13 | 2004-04-30 | Inhibitex, Inc. | Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| US20040151737A1 (en) | 2003-02-05 | 2004-08-05 | University Of Tennessee | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
| NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2526753A1 (en) * | 2003-05-29 | 2004-12-23 | Inhibitex, Inc. | Sdr proteins from staphylococcus capitis and their use in preventing and treating infections |
| AU2005286607B2 (en) * | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2006076058A1 (en) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| WO2006138627A2 (en) | 2005-06-16 | 2006-12-28 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| AU2007221321B2 (en) | 2006-02-22 | 2012-06-28 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use |
| CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
| JP5456658B2 (ja) * | 2007-03-30 | 2014-04-02 | メディミューン，エルエルシー | 抗体製剤 |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| CN101302504B (zh) * | 2007-05-11 | 2011-12-21 | 上海高科联合生物技术研发有限公司 | 一种抗体亲和层析纯化溶葡萄球菌酶的方法 |
| RS52305B (en) | 2007-07-16 | 2012-12-31 | Genentech Inc. | ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE |
| PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| US20090162379A1 (en) * | 2007-10-01 | 2009-06-25 | Magnus Hook | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor |
| ES2450755T3 (es) | 2007-10-19 | 2014-03-25 | Genentech, Inc. | Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco |
| ES2587392T3 (es) | 2008-01-31 | 2016-10-24 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| AU2009209598B2 (en) | 2008-01-31 | 2012-07-26 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Treatment of microbial infections |
| WO2010005513A2 (en) | 2008-06-30 | 2010-01-14 | The Texas A&M University System | Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
| SI2445522T1 (sl) * | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
| HUE038277T2 (hu) | 2009-07-15 | 2018-10-29 | Aimm Therapeutics Bv | Gram-pozitív baktériumokra specifikus kötõvegyületek |
| WO2011007004A1 (en) | 2009-07-16 | 2011-01-20 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Treatment of infections |
-
2010
- 2010-07-15 HU HUE10734844A patent/HUE038277T2/hu unknown
- 2010-07-15 JP JP2012520555A patent/JP6192294B2/ja not_active Expired - Fee Related
- 2010-07-15 TR TR2018/09128T patent/TR201809128T4/tr unknown
- 2010-07-15 ES ES10734844.3T patent/ES2673323T3/es active Active
- 2010-07-15 SG SG2012002622A patent/SG177653A1/en unknown
- 2010-07-15 CN CN201080041138.6A patent/CN102666583B/zh not_active Expired - Fee Related
- 2010-07-15 AU AU2010271582A patent/AU2010271582B2/en not_active Ceased
- 2010-07-15 TW TW104126578A patent/TW201610153A/zh unknown
- 2010-07-15 BR BR112012000953A patent/BR112012000953A8/pt not_active Application Discontinuation
- 2010-07-15 DK DK10734844.3T patent/DK2454284T3/en active
- 2010-07-15 PL PL10734844T patent/PL2454284T3/pl unknown
- 2010-07-15 MX MX2014012186A patent/MX350234B/es unknown
- 2010-07-15 US US12/837,358 patent/US20110020323A1/en not_active Abandoned
- 2010-07-15 TW TW099123405A patent/TWI502068B/zh not_active IP Right Cessation
- 2010-07-15 NZ NZ616921A patent/NZ616921A/en not_active IP Right Cessation
- 2010-07-15 WO PCT/NL2010/050456 patent/WO2011008092A2/en active Application Filing
- 2010-07-15 NZ NZ598063A patent/NZ598063A/en not_active IP Right Cessation
- 2010-07-15 EP EP10734844.3A patent/EP2454284B1/en not_active Not-in-force
- 2010-07-15 EA EA201390967A patent/EA031447B1/ru not_active IP Right Cessation
- 2010-07-15 SG SG10201704269RA patent/SG10201704269RA/en unknown
- 2010-07-15 KR KR1020127003839A patent/KR101832201B1/ko active IP Right Grant
- 2010-07-15 AR ARP100102587A patent/AR077756A1/es unknown
- 2010-07-15 SI SI201031701T patent/SI2454284T1/en unknown
- 2010-07-15 CA CA2768204A patent/CA2768204A1/en not_active Abandoned
- 2010-07-15 CN CN201510639968.3A patent/CN105440133A/zh active Pending
-
2011
- 2011-11-28 US US13/305,659 patent/US8617556B2/en not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217497A patent/IL217497A/en not_active IP Right Cessation
- 2012-01-17 ZA ZA2012/00363A patent/ZA201200363B/en unknown
-
2013
- 2013-03-05 US US13/786,206 patent/US9399673B2/en active Active
- 2013-03-05 US US13/786,215 patent/US9090677B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,715 patent/US9266943B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 ZA ZA2014/00644A patent/ZA201400644B/en unknown
-
2015
- 2015-04-01 IL IL238074A patent/IL238074A/en not_active IP Right Cessation
- 2015-06-02 US US14/728,826 patent/US9458228B2/en not_active Expired - Fee Related
- 2015-10-22 IL IL242207A patent/IL242207A0/en unknown
- 2015-12-28 US US14/981,643 patent/US9688745B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001939A patent/JP2016135771A/ja active Pending
- 2016-08-24 US US15/246,301 patent/US9927428B2/en not_active Expired - Fee Related
- 2016-09-05 HK HK16110533.5A patent/HK1222418A1/zh unknown
- 2016-10-27 AU AU2016250398A patent/AU2016250398B2/en not_active Ceased
-
2018
- 2018-02-20 US US15/900,589 patent/US20180292391A1/en not_active Abandoned
- 2018-04-04 JP JP2018072444A patent/JP2018134089A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201809128T4 (tr) | Gram-pozitif bakterilere spesifik bağlanan bileşikler. | |
| Varshney et al. | A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia | |
| DiGiandomenico et al. | A multifunctional bispecific antibody protects against Pseudomonas aeruginosa | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| JP6182152B2 (ja) | 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療 | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| RU2015121624A (ru) | Антитела к поверхностным детерминантам s. aureus | |
| JP2020037555A5 (tr) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| JP2014508748A5 (tr) | ||
| SI2857418T1 (en) | Antibodies to clostridium difficile toxins and their use | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2015121617A (ru) | Способы лечения заболеваний, ассоциированных с s. aureus | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| JP2014529610A5 (tr) | ||
| JP2016047828A5 (tr) | ||
| RU2011146424A (ru) | Антитела или их фрагменты, направленные против эпитопа стафилококка золотистого (staphylococcus aureus) | |
| AU2011295702A1 (en) | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof | |
| WO2014061783A1 (ja) | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 | |
| Kabir et al. | Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide | |
| US8940304B2 (en) | Monoclonal antibodies against the PBP2-A protein and homologous sequences for the treatment of infections by and immunodiagnostics of bacteria of the firmicutes phylum | |
| NZ606828A (en) | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof | |
| AU2010282162B2 (en) | Monoclonal antibodies against the PBP2-a protein and homologous sequences for the treatment of infections by and immunodiagnostics of bacteria of the firmicutes phylum |